drugset / Trial / NCT02307396

Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients

NCT02307396

Phase 4 Completed 21 enrolled Technical University of Munich
RandomizedParallel-groupSingle-blindTreatment

Summary

The main objective of the trial is to evaluate, how long an antipsychotic relapse-prevention should be continued and to which time a patient with schizophrenia is protected enough, so that a withdrawal or reduction of the medication seems appropriate. Relapse is defined as primary outcome.

Timeline

Start
2015-02-01
Primary completion
2016-06-22
Completion
2016-06-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Amisulpride Small molecule
Subject Benperidol Small molecule
Subject Bromperidol Small molecule
Subject E-FLUPENTIXOL Small molecule
Subject Fluphenazine Small molecule
Subject Fluspirilene Small molecule
Subject Haloperidol Other / unclassified
Subject Olanzapine Small molecule
Subject Paliperidone Unknown
Subject Perazine Small molecule
Subject Perphenazine Small molecule
Subject Pimozide Small molecule
Subject Quetiapine Small molecule
Subject Risperidone Other / unclassified
Subject Sertindole Small molecule
Subject Sulpiride Small molecule
Subject Thioridazine Unknown
Subject Ziprasidone Small molecule
Subject Zuclopenthixol Unknown